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and restoration of tis-
sue microarchitecture.
Visceral leishmaniasis is an important yetneglectedparasitic disease causedby infectionwith
Leishmania donovani or L infantum. Disease manifestations include fever, weight loss,
hepatosplenomegaly, immune dysregulation, and extensive hematological complications.
Thrombocytopenia is a dominant hematological feature seen in both humans and
experimental models, but the mechanisms behind this infection-driven thrombocytopenia
remain poorly understood. Using a murine model of experimental visceral leishmaniasis
(EVL), we demonstrated a progressive decrease in platelets from day 14 after infection,
culminating in severe thrombocytopenia by day 28. Plasma thrombopoietin (TPO) levels
were reduced in infected mice, at least in part because of the alterations in the liver
microenvironment associated with granulomatous inflammation. Bone marrow (BM)
megakaryocyte cytoplasmic maturation was significantly reduced. In addition
to a production deficit, we identified significant increases in platelet clearance.
L donovani–infected splenectomized mice were protected from thrombocytopenia
compared with sham operated infected mice and had a greater response to exogenous TPO.
Furthermore, infection led to higher levels of platelet opsonization and desialylation, both
associated with platelet clearance in spleen and liver, respectively. Critically, these changes
could be reversed rapidly by drug treatment to reduce parasite load or by administration of
TPO agonists. In summary, our findings demonstrate that the mechanisms underpinning
thrombocytopenia in EVL are multifactorial and reversible, with no obvious residual
damage to the BM microenvironment.
Introduction
Visceral leishmaniasis (VL) is a neglected parasitic disease caused by the protozoan parasites
Leishmania donovani and L infantum. Approximately 50 000 to 90 000 cases and ;20000 deaths
occur every year, mostly in Brazil, East Africa, and India.1,2 Fever, weight loss, and hepatosplenomegaly
are common clinical findings, along with hematological complications and immune dysregulation.3,4
Leishmania reside and replicate inside tissue macrophages as nonmotile amastigote forms and survive
by hijacking a variety of innate and acquired immune response pathways at the cellular and tissue level to
subvert macrophage leishmanicidal activity.4,5
Thrombocytopenia is one of the predominant hematological features of many viral, bacterial, and
parasitic infections with complex underlying pathogeneses.6-8 Infection has been associated with bone
marrow (BM) suppression that leads to reduced platelet production, defective thrombopoietin (TPO)
production, and enhanced peripheral clearance.8-11 In addition to alterations in platelet production, the
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evidence supports alterations in the pathways for removal of
platelets as an important contributor to thrombocytopenia. For
example, antiplatelet antibodies detected in infections such as
hepatitis-C,12 HIV,13 and immune thrombocytopenia (ITP) second-
ary to infection,14 can lead to excessive platelet clearance by tissue
macrophages.15 Furthermore, exposure of galactose residues on
the membranes of desialylated platelets in sepsis has been shown
to make them more prone to clearance by hepatocytes or Kupffer
cells, providing an alternate route for platelet clearance outside of
the spleen.16-18 Collectively, these changes may lead to disease-
related cytopenias and hematological complications.19-22
Thrombocytopenia, along with anemia, is a common clinical finding
in patients with VL and in experimental models of disease, with the
mechanisms underlying anemia being the more well studied. For
example, experimental studies using murine models have shown
that L donovani infection triggers emergency hematopoiesis and
affects the hematopoietic stem cell (HSC) compartment through
exhaustion and reduced potential for self-renewal.23,24 In addition,
dysfunctional medullary erythropoiesis may contribute to anemia.25
Little is known, however, about the mechanisms responsible for
thrombocytopenia during this disease, beyond the identification of
a high prevalence of platelet-binding antibodies in dogs with acute
canine VL.26,27 VL is notable in affecting primarily 3 major systemic
organs (the liver, BM, and spleen), each of which is also involved in
the production, regulation, and clearance of platelets under
physiological and pathological conditions. At homeostasis, normal
microarchitectural organization of these tissues is critical for the
production and clearance of platelets.28-30 During VL, major micro-
architectural changes occur, including prolific hepatic granulomatous
inflammation,31 BM hypocellularity or myelodysplasia,3,32,33 and
remodeling of splenic red and white pulp.34 The impact of these
changes in terms of drivers of platelet production and clearance are
unknown.35 In particular, splenic macrophages are highly effective at
removing aged or damaged blood cells, and these functions can be
enhanced as a consequence of infection-associated splenomegaly
and bystander cytokine-dependent activation.31,36,37
In this study, we showed that thrombocytopenia is a feature of
experimental VL (EVL) in a C57BL/6 mouse model and character-
ized contributing pathways at the tissue, cellular, and molecular
levels. Using a combination of surgical intervention, drug treatment,
and cytokine reconstitution, we found that L donovani infection led
to alterations in the megakaryocyte (MK) demarcation membrane
system (DMS), commensurate with decreased hepatic production
and plasma concentrations of TPO and platelet membrane changes
that would facilitate enhanced platelet clearance in both spleen and
liver. Hence, multiple pathways contribute to the evolution of
reversible thrombocytopenia during this infection.
Methods
Ethics statement
Ethical approval for the study was obtained from the Animal Welfare
and Ethical Review Board of the Department of Biology, University
of York. All procedures were performed under the authority of
United Kingdom Home Office Project License P49487014.
Mice, infection, and experimental manipulation
Female C57BL/6 wild-type (WT) mice 6 to 8 weeks of age, bred
and maintained at the Biological Services Facility, University of York,
were used for all experiments. The mice were housed in individ-
ually ventilated cages at 20 to 21°C and 56% humidity under
specific-pathogen–free conditions with quarterly health screening
(Federation of European Laboratory Animal Science Associations
standards 67M and 51M) and provided with food and water ad
libitum. Sham operated and splenectomized C57BL/6 mice were
purchased from Jackson Laboratories and allowed to recover for
3 weeks before infection. The mice were infected via the IV route
with 33 107 amastigotes of an Ethiopian strain of L donovani (LV9)
without anesthesia. Control age-matched mice were housed
in similar conditions. As required, infected mice were treated
with a single IV dose (8 mg/kg) of AmBisome (Gilead Sciences
International Ltd, Cambridge, United Kingdom), resuspended in
sterile 5% dextrose in distilled water. As required, sham operated
and splenectomized-infected mice were treated with exogenous
human recombinant TPO (rTPO; Zymogenetics, Seattle, WA) at
a dose of 50 mg/g bodyweight intraperitoneally, daily for 5 consecutive
days. ITP was induced by a single intraperitoneal dose of 0.2 mg/g
of rat anti-mouse CD41 monoclonal antibody (MWReg30; BD
Pharmingen).38 All mice were euthanized by CO2 inhalation
and cervical dislocation at specified times. The parasite burden
was determined in Giemsa-stained tissue impression smears
and expressed as Leishman-Donovan units (LDUs), using the following
formula: LDU 5 number of amastigotes/1000 cell nuclei 3 organ
weight (grams).
Blood collection and analysis
Blood was collected in EDTA-coated tubes (Microvette CB300
EDTA; Sarstedt, Nümbrecht, Germany) from a lateral tail vein of
infected and uninfected mice at specific time points. Blood analysis
was performed on a scil Vet abc Plus1 blood counter (Scil Animal
Care Company, Dumfries, United Kingdom). For blood smears, air-
dried, methanol-fixed blood smear slides were stained with the
Hemacolor staining kit (Merck, Darmstadt, Germany) per the
manufacturer’s guidelines.
Platelet assays
Mice were bled via cardiac puncture after they were anesthetized by
isoflurane inhalation in a secure chamber (Apollo TEC3 Isoflurane
Vaporizer; Sound Veterinary Equipment, Rowville, VIC, Australia),
and platelets were isolated by using established protocols.39
Freshly isolated platelets were stained with anti-CD41 FITC
antibody (1:200; cat no. 133904; BioLegend) for 30 minutes at
room temperature (RT). The platelets were incubated with either
(30 minutes at RT) conjugated anti-mouse IgG AF647 (1:500; cat
no. A-32728; Invitrogen) and IgM PE-Cy7 (1:500; cat no. 552867;
BD Biosciences, San Jose, CA) antibodies for anti-platelet antibody
detection or biotinylated lectins (Ricinus communis agglutinin-1
[RCA-1] and Maackia amurensis lectin-2 [MAL-2]; 0.5 mg/mL;
Vector Laboratories) followed by streptavidin-labeled phycoerythrin
(1:200; cat no. 554061; BD Biosciences) for 15 minutes for
identifying desialylated platelets. The platelets were washed with
buffer (150 nM NaCl and 50 nM HEPES, [pH 6.5] at RT) and
acquired on a BD LSR II Fortessa flow cytometer (BD Biosciences).
Unstained, single antibody–stained, and neuraminidase-treated
(3 U/mL at 37°C for 30 minutes; Invitrogen) platelets were used
as controls. Data were analyzed with FlowJo, v10.6.2 software
(FlowJo, Ashland, OR) and FCS Express 7 (De Novo Software,
Pasadena, CA).





































































































Quantification of circulating TPO
Circulating TPO levels were measured in the serum samples
of infected and uninfected mice with a Mouse Thrombopoietin
Quantikine ELISA Kit (MTP100; R&D Systems, Minneapolis. MN),
per the manufacturer’s guidelines.
Measurement of Thpo mRNA accumulation
RNA was extracted from liver samples with Micro RNeasy kits
(Qiagen), per the manufacturer’s guidelines, and RNA quality and
quantity were assessed with a NanoDrop 2000 spectrophotometer
(Thermo Fisher Scientific). The synthesis of cDNA was performed
with a High-Capacity cDNA Reverse Transcription kit (Thermo Fisher
Scientific) using the manufacturer’s protocol. Duplex quantitative
polymerase chain reaction (qPCR) was performed with TaqMan
gene expression assays (Applied Biosystems, Thermo Fisher Scien-
tific) with a Thpo FAM and a Hrpt VIC dye-labeled probes. Real-time
PCRs (RT-PCRs) were performed on QuantStudio 3 Real-Time
PCR system (Applied Biosystems, Thermo Fisher Scientific) under
the following cycling conditions: 95°C for 20 seconds followed by
40 cycles of 95°C for 1 second and 60°C for 20 seconds. Data
were analyzed using the QuantStudio Design and Analysis
software (Thermo Fisher Scientific). Thpo mRNA expression levels
were normalized to the Hprt housekeeping gene by using DDCt
calculations. Relative expression levels between control and exper-
imental groups were calculated using 22DDCt.
Histological analysis
The methodology for processing BM and liver samples for light and
electron microscopy, and the methodology for image analysis to
identify changes in the MK DMS and for evaluating expression of
TPO by hepatocytes are provided in the supplemental Methods.
Statistical analysis
All the downstream tissue analyses were performed by researchers
blinded to the treatment groups and were analyzed using Prism 8.0
software (GraphPad, San Diego, CA). When comparing 2 groups,
the unpaired Student t test or Mann-Whitney U test was applied,
depending on the distribution of data. An analysis of variance
(ANOVA) was used for multiple comparisons followed by the post
hoc Tukey’s test. P , 0.05 was taken as significant.
Results
L donovani infection results in
progressive thrombocytopenia
We used a well-characterized C57BL/6 mouse model of L
donovani infection to study the mechanisms of thrombocytopenia
(Figure 1A). As the early kinetics of infection have been well-
described in both spleen and liver,23,25 we performed sequential
blood sampling over a 28-day period before termination of the
experiment. As expected, at the study end point, high parasite
burdens in liver and spleen were recorded, along with significant
hepatosplenomegaly (Figure 1B-C) and mild anemia25 (supple-
mental Figure 1). To evaluate the kinetics of development of
thrombocytopenia, blood samples were taken weekly. Platelet
counts in uninfected mice remained consistent over the time course
of these experiments, indicating that sequential sampling had
minimal effects. In infected mice, the platelet count was similar to
that of control mice at day 7 post infection (PI). but showed
a progressive decline from day 14 PI, with all mice being severely
thrombocytopenic by day 28 PI (Figure 1D, left). Platelets in
infected mice were also significantly larger than those in uninfected
mice (mean platelet volume [MPV]; 7.58 6 0.36 mm3 vs 5.6 6 0.2
mm3 in infected vs uninfected mice at day 28 PI; Figure 1D, right).
Giemsa-stained blood smears confirmed the presence of giant
platelets in infected mice (Figure 1E). In contrast to the findings in
C57BL/6 mice, we found that BALB/c mice, another strain
susceptible to L donovani infection, showed only minimal levels
of thrombocytopenia (supplemental Figure 2). Thus, infection of
C57BL/6 mice provides a more appropriate model for the study of
this aspect of human disease, in addition to its value in studying the
alterations in erythropoiesis that lead to anemia.25
BM MK ultrastructure and functional capacity in EVL
We first investigated whether thrombocytopenia is caused by
defective production of platelets in mice with L donovani infection
by examining the gross and ultrastructural morphology of BM MKs.
No significant difference in the number of BMMKs was observed on
hematoxylin and eosin–stained BM sections at the time of maximal
thrombocytopenia (Figure 2A). Maturation of MKs is characterized
by the development of a unique membrane system, the DMS, which
ultimately divides the cytoplasm during platelet formation.40 To
assess whether the DMS of BM MKs in infected mice was altered,
we applied quantitative image analysis to transmission electron
microscopy (TEM) images of BM MKs (supplemental Figure 3).
Analysis of the perimeter of the DMS indicated that these membranes
were significantly reduced in MKs in infected mice, compared with
uninfected mice (Figure 2B). Reduction in the DMS of MKs in infected
mice suggests that their capacity to produce platelets may be
impaired as a consequence of infection. Platelet territories were
also less pronounced in MKs in infected mice compared with those
in uninfected mice, further suggesting a reduced capacity to produce
platelets (Figure 2C).
To determine the functional capacity of MKs for platelet production
by using an independent approach, we used a well-characterized
model of anti-CD41–driven induced ITP.38 Infected and uninfected
mice were treated with anti-CD41 mAb and bled for platelet counts
at the time points specified in Figure 2D. Administration of anti-
CD41 mAb to uninfected and day-28–infected mice led in both
cases to a rapid decrease in platelet count followed by a period of
recovery to levels above that observed before treatment (Figure 2E).
Importantly, the rate of platelet recovery was comparable between
groups when normalized to baseline platelet counts (Figure 2F). As
restoration in platelet count after experimental ITP is commonly
attributed to new platelet production by MKs, these data suggest
that the capacity for new platelet production is intact in infected
mice, but that extrinsic factors not present in uninfected mice limit
the extent to which the platelet count can be restored. A slight
reduction in the MPV of anti-CD41–treated infected mice was
noted. No difference in the splenic LDUs (146.2 6 35.07 vs 177.9
6 54.46) and spleen weights (0.7196 6 0.304 g vs 0.8298 6
0.1736 g) were observed between infected anti-CD41–treated and
nontreated infected mice. Furthermore, anti-CD41 treatment of
infected mice partially restored the integrity of the DMS (17.66 6
5.68 mm vs 11.84 6 4.94 mm, anti-CD41–treated infected mice
and untreated infected mice, respectively Figure 2H). Although no
significant difference in the DMS of uninfected anti-CD41–treated





































































































mice was noted, territories of developing platelets were prominent
in anti-CD41–treated uninfected and infected mice (Figure 2G).
TPO production is compromised during chronic EVL
Alterations in MK capacity for platelet production may also
reflect changes in the availability of TPO, a critical promotor of
megakaryopoiesis and platelet production derived largely from
hepatocytes.41,42 Given the role of the liver as a target organ in
VL, we next assessed the production of TPO during L donovani
infection, by measuring circulating unbound TPO levels in un-
infected and infected mice. TPO levels in infected mice were
significantly reduced at day 28 PI compared with those in
uninfected mice (600.527 6 25.82 pg/mL vs 75.8935 6 26.75
pg/mL, in uninfected and infected mice respectively; Figure 3A).
We also found a 50% reduction in liver Thpo mRNA in infected
mice compared with uninfected mice, as determined by quantitative
RT-PCR (qRT-PCR; Figure 3B). To better understand the effects of
L donovani infection on hepatic TPO production, we stained liver
sections of uninfected and day-28–infected mice with anti-TPO
antibody (Figure 3C) and analyzed the resulting staining pattern by
quantitative morphometry and segmentation analysis. We observed
a reduction in the number of TPO1 hepatocytes per unit area,
most probably a consequence of granulomatous inflammation;
an increase in the number of nonparenchymal inflammatory cells
(Figure 3D, left); and an increase in F4/801 Kupffer cells per unit
area (Figure 3D, right). In addition, in liver tissues stained with the
anti-TPO antibody and analyzed using an in-house image analysis
pipeline, we determined the median fluorescence intensity (MFI) of
TPO1 hepatocytes in uninfected vs day-28–infected mice and at
different distances (0-30 and 30-60 mm) from the margin of
granulomas in the infected mice (supplemental Figure 4). Based on
this analysis, TPO expression was marginally but significantly higher
in hepatocytes closer (0-30 mm) to granulomas, compared with
hepatocytes found farther away (30-60 mm; Figure 3E). Together,
these data are suggestive of spatial regulation of TPO production
during hepatic infection.
Splenomegaly-associated platelet clearance in
L donovani–infected mice
Although the data indicate significant changes in the host capacity
to produce platelets during L donovani infection, changes in
reticuloendothelial function, notably associated with splenomegaly,
may also have an impact on thrombocytopenia through enhanced
platelet clearance. To determine the role of splenomegaly in platelet
clearance, sham operated and splenectomized mice were infected
with L donovani, and platelet counts were assessed. In control
uninfected mice, splenectomy had little impact on platelet count,
suggesting that the spleen is not essential for maintaining platelet
homeostasis (Figure 4A). In contrast to the pronounced thrombo-
cytopenia observed in sham operated infected mice, splenectom-
ized infected mice were partially protected from thrombocytopenia
(P , .001) and had reduced MPV (Figure 4A). We then exposed
sham operated and splenectomized infected mice to rTPO to
determine the extent to which this cytokine would reconstitute the





































































Figure 1. Thrombocytopenia associated with experimental VL. (A) C57BL/6 WT mice were infected with 3 3 107 L donovani amastigotes IV for 28 days. Mice were
bled every week via a tail vein for platelet counts, and tissues were harvested at day 28 PI for further analysis. (B) The parasite burden was calculated as LDUs on Giemsa-
stained liver (n 5 18) and spleen (n 5 17) impression smears on day 28 PI. (C) Postmortem liver and spleen weights were measured in infected (n 5 19) and uninfected
(n 5 9) mice. (D) Platelet count (left) and MPV (right) were monitored weekly after infection in infected (n 5 12) and uninfected (n 5 15) mice. (E) Blood smears of uninfected
(i) and infected (ii) mice show the presence of giant platelets on the infected mouse blood smear. Representative normal platelets (thin red arrows) and giant platelets
(thick red arrow) are indicated. Original magnification 363. All data were pooled from 3 different independent experiments and analyzed using the unpaired Student t test
comparing the mean 6 SD of uninfected vs infected at each time point. **P , .01; ****P , .0001.





































































































to sham treated infected mice raised platelet counts by approximately
twofold, compared with the range in untreated mice, but this increase
remained below the normal range of counts in uninfected mice. These
data indicate that rTPO can stimulate platelet production in infected
mice, but that there remains a barrier to restoring a homeostatic
number of platelets. In contrast, after splenectomy, rTPO elevated the
number of platelets in infected mice to supraphysiological levels
(Figure 4B). Collectively, these data indicate that, despite the infection-
associated changes in MKs noted herein, platelet production is
restored by exogenous rTPO and that splenomegaly is a limiting factor
governing the number of platelets in the blood.
Pathways for platelet clearance
Our results indicate that during L donovani infection, there are
changes in hepatocyte TPO production and in splenic platelet
clearance. To determine the extent to which these events are related
to modifications of the platelet membrane and their interaction with
host cells, we first determined whether infection is associated with
the production of anti-platelet antibodies (Figure 4C). Infected mice
showed a significant increase in the frequency of IgG-bound platelets
compared with uninfected mice (Figure 4D) and in the amount of IgG
bound (MFI 5242.666 811.42 vs 4596 312.54; mean6 standard
d7 d21d14
Bleeding time-points











































































































































Figure 2. Alteration to BM megakaryocyte form and function during experimental VL. (A) BM MKs were counted manually on hematoxylin and eosin–stained frozen
sections in 10 random fields of view for uninfected (n 5 4) and infected (n 5 4) mice. TEM (FEI Tecnai 12G2) was performed on femur sections of uninfected and day-
28–infected mice. Images were analyzed by creating outlines of demarcation membranes with Fiji ImageJ software (supplemental Figure 3). (B) Perimeters were then calcu-
lated on 25 uninfected and 46 infected mouse BM MKs. Data represent the mean 6 standard error of the mean (SEM) across individual mice. The unpaired Student t test was
applied to the means of the perimeter of membranes; ****P , .0001, in uninfected vs infected mice. (C) Representative TEM images of BM MKs in uninfected (i-ii) and infected
(iii-iv) mice, showing the presence of multilobulated nucleus (N) and DMS (d) within the cytoplasm. Bar represents 5 mm. Original magnification 32000. (D) Anti-CD41 mAb-
induced ITP in infected and uninfected mice. A single intraperitoneal injection (0.2 mg/g body weight) of anti-CD41 mAb (clone, MWReg30) was administered, followed by
collection of blood for platelet counts at the specified time points. Platelet count (E) and rate of decline and recovery of platelet count (F) in uninfected and infected mice after
anti-CD41 mAb-induced thrombocytopenia. Data were pooled from 3 independent experiments with uninfected (n 5 3), anti-CD41–treated uninfected (n 5 9), infected
(n 5 5), and infected1anti-CD41–treated (n 5 10) mice. (G) Representative TEM images of BM MK from infected anti-CD41–treated (i-ii) and uninfected anti-CD41–treated
(iii-iv) mice, showing DMS and platelet areas. Bar represents 5 mm. Original magnification 32000. (H) The perimeter of the demarcation membranes of anti-CD41–treated
uninfected (n 5 20) and anti-CD41–treated infected (n 5 30) mice. The dotted line corresponds with the mean of the perimeter of the DMS in nontreated infected mice.
Data are expressed as means 6 SEM and analyzed with the unpaired Student t test. *P , .05.





































































































deviation [SD] in infected vs uninfected mice, respectively). Similarly,
infected mice had a higher frequency of IgM-bound platelets
(Figure 4D) and also bound greater amounts of IgM compared with
platelets from uninfected mice (MFI 2068 6 594.47 vs 420.5 6
259.50; mean 6 SD in infected vs uninfected mice).
Platelet binding to the Ashwell Morrel receptor is associated with
desialylation and leads to STAT3 signaling.43 Platelet desialylation
results in the exposure of galactose-containing moieties that can be
detected using galactose-binding lectins.16 To examine the sialylation
status of platelets in infectedmice, freshly isolated platelets were stained
with 2 galectins: R communis agglutinin-1 (RCA-1) and M amurensis
lectin-2 (MAL-2). By flow cytometry, only a low frequency (;5%) of
platelets in uninfected mice were stained with either lectin, as expected
from results of previous studies.44,45 In contrast, ;60% of circulating
platelets in infected mice were lectin positive, indicating a marked shift
toward desialylation (Figure 4E-F). Thus, L donovani infection is
associated with distinct platelet surface changes that facilitate their
interaction with both splenic macrophages and hepatocytes.
Posttreatment recovery of platelet count
Clinically and in experimental models of L donovani infection,
successful drug treatment can allow for selective and temporal
restoration of homeostasis within the immune and hematological
compartments.3,46 We therefore sought to examine the extent to
which processes that affected platelet count recovered after
treatment with AmBisome, a commonly used drug for human
VL.47 Platelet counts were monitored in infected mice weekly
after AmBisome treatment. Platelet counts (Figure 5A) and MPV
(Figure 5B) showed a progressive recovery, reaching normal
range within 3 weeks after treatment, with MPV normalizing
shortly thereafter. Drug treatment was associated with reduced
hepatomegaly, as expected from the resolution of granulomatous
inflammation46 (Figure 5C), and that result was accompanied by
restoration of serum TPO levels (Figure 5D) and hepatic Thpo
mRNA accumulation (Figure 5E). Slow but progressive reduction
in splenomegaly was also noted in drug-treated infected mice
after treatment (Figure 5F).
Discussion
Hematological complications including anemia, thrombocytopenia,
and pancytopenia have been widely reported in patients with VL and
mirrored in many respects in experimental models of the disease,3,25,48
but the underlying mechanisms of thrombocytopenia remain poorly
understood. In this study, we showed, in an experimental mouse
model of VL, that thrombocytopenia is multifactorial and involves
coordinated changes in the platelet surface that lead to both
a reduction in production capacity mediated through the TPO/MK






























































































Figure 3. Thrombopoietin regulation during L donovani infection. (A) Circulating levels of TPO at day 28 PI were measured in the serum samples of infected and
uninfected C57BL/6 mice. (B) Hepatic mRNA accumulation measured using qRT-PCR on postmortem liver samples of infected and uninfected mice. (C) Representative
immunofluorescent liver images of uninfected (i) and infected (ii) mice, stained with anti-TPO antibody (green), F4/80 (red), and 49,6-diamidino-2-phenylindole (white). Images
captured with an LSM 710 confocal microscope at 633 resolution. Bar represents 50 mm. Segmentation analysis was performed with Strataquest image analysis software
on immunofluorescent liver images and expressed as cell count per unit area of infected and uninfected livers (D) and MFI of TPO1 cells in infected livers (E). MFIs were
calculated for TPO1 hepatocytes at 0 to 30 mm and 30 to 60 mm from the margin of granuloma in infected mice. Data are representative of 5 uninfected and 5 infected mice
from a single experiment, analyzed with the unpaired Student t test (A-B) and the nonparametric Mann-Whitney U test (D-E). **P , .01; ***P , .001; ****P , .0001.





































































































First, we showed that infected C57BL/6 mice develop pro-
gressive thrombocytopenia with the presence of giant platelets
in circulation. Although the number of BM MKs was similar in
control and infected mice, we found that MK maturation was
altered in infected mice, leading to clear differences in de-
velopment of the DMS. Defective MKs with a reduced DMS have
been seen in congenital thrombocytopenias, such as MYH9-
related disorders,49 but not previously reported in a model of
parasitic infection. The demarcation membranes in infected mouse
BM MKs were 1.75 times reduced, similar to those observed in
congenital MYH9-related disorders.49 Furthermore, we showed
that these membranes are recoverable after stimulation of MKs
to produce platelets, as evidenced by the increased territories of
newly developing platelets after the novel approach of coinduc-
tion of ITP with anti-CD41 mAb on the background of chronic
L donovani infection. Infected mice showed a pattern of platelet
count recovery similar to that in uninfected mice, suggesting that
MKs in infected mice retain some functional capability and that
other factors contribute to keeping the number of circulating
platelets low.
Second, multiple lines of evidence indicated that infection is
associated with alteration in TPO production in the liver. Total
hepatic mRNA accumulation was decreased, although this may
reflect an influx of inflammatory cells leading to dilution of hepatocyte
mRNA representation. This finding was supported by a reduc-
tion in the number of TPO-expressing hepatocytes detected
by immunohistochemistry. Under normal conditions, levels of
circulating TPO are inversely proportional to platelet count,
although this equilibrium is often dysregulated in hematological
and hepatic disease.50-52 In this study, we found a significant
decrease in the levels of circulating TPO in infected mice at day
28 PI. Previous studies have shown that the regulation of TPO
production is complex and may be independent of both platelet
count and circulating levels, as shown by normal levels in ITP
and increased levels in aplastic anemia.51 In addition, our results
show a reduction in the number of TPO1 hepatocytes, most
probably related to hepatic granuloma formation. The expression
of TPO, as assessed by MFI, was higher in hepatocytes closer
to the margin of granulomas, compared with the hepatocytes

























































































































































































































































































Figure 4. The role of tissue-mediated platelet clearance in L donovani–induced thrombocytopenia. Splenectomized and sham operated mice were infected with
L donovani amastigotes for 28 days, similar to WT mice, and bled for the blood counts. (A) Platelet count and MPV of the study groups (n 5 15 for each group). Data were
pooled from 3 independent experiments and analyzed using ANOVA with the post hoc Tukey’s test comparing mean 6 SD of all groups. (B) Platelet count and MPV of sham/
infected (n 5 4) and splenectomized/infected (n 5 5) mice after administration of exogenous rTPO (50 mg/g bodyweight) for 5 consecutive days. Data are representative of
a single experiment and analyzed with the unpaired Student t test comparing the mean 6 SD between 2 groups. (C) Flow cytometric analysis was performed for the estimation
of IgG- and IgM-bound platelets in the circulation of infected mice. Representative histograms show the gating strategy for IgG- and IgM-bound platelets in uninfected and
infected mice. (D) Dot plots represent the percentage of total platelets with bound IgG and IgM in uninfected (n 5 5) and infected (n 5 15) mouse platelets. Data are
representative of 2 independent experiments and were analyzed with the unpaired Student t test comparing the mean 6 SD between the 2 groups. (E) Flow cytometric
analysis was performed on the freshly isolated platelets for the estimation of desialylated platelets in circulation. Histograms representative of gating strategy for lectin1 plate-
lets in infected (i) and uninfected control (c) mice. Neuraminidase-treated platelets (n) were used as the positive control for each lectin. (F) Percentage of RCA-1 and MAL-2
lectin1 platelets from uninfected (n 5 4) and infected (n 5 15) mice. Data were pooled from 2 independent experiments and analyzed using the unpaired Student t test
comparing the mean 6 SD between 2 groups. *P , .05; **P , .01; ***P , .001; ****P , .0001.





































































































produced by inflammatory cells in the activation of JAK-STAT
signaling in hepatocytes.43 Although further studies are needed
to confirm a link between form and function of granuloma and
hepatocyte production of TPO, our data provide the first indication
of spatial regulation of TPO production in the hepatic microenvi-
ronment during infection.
Third, we observed that platelets in infected mice were more
frequently desialylated than those in uninfected mice. Excessive
platelet desialylation has been shown in sepsis and infections that
could lead to enhanced platelet clearance by hepatocytes.12,53,54
Although increased platelet desialylation has been proposed to
increase the production of TPO by binding to the Ashwell Morrel
receptor expressed by hepatocytes,16 this notion has yet to be
formally demonstrated in the context of this model of VL. However,
disruption of normal hepatic microarchitecture and granulomatous
inflammation may alter the signaling pathways for the production of
TPO. We have also observed through the application of holoto-
mography that platelets from L donovani–infected mice have
additional alterations in their physicochemical properties, such as
sphericity, refractive index, and dry mass,55 although it remains to be
determined whether these affect the interaction of platelets with
hepatocytes.
Finally, for the first time, we have shown in a model of VL the impact
of splenectomy on the extent of thrombocytopenia. Splenectomized
infected mice had markedly less severe thrombocytopenia than
sham operated mice and a better response to exogenous rTPO.
Splenomegaly is one of the most common clinical findings in
human VL and experimental models. RP macrophages, which act
as a major reservoir for the parasite, remain highly phagocytic.37
Macrophage clearance of platelets is often associated with Fc-
dependent phagocytosis, and we were also able to demonstrate
the presence of antibodies against platelets in circulation. Anti-
platelet antibodies have been detected in ITP and infection-induced
thrombocytopenia.12 Our data also confirm that platelets are
opsonized by anti-platelet IgG and IgM antibodies in murine VL,
as previously described in canine VL.26 In this model of infection,
mild anemia is also evident from ;4 weeks PI, but in contrast to
thrombocytopenia, anemia is not affected by splenectomy.25 This
result is in keeping with the view that, despite both compensatory
erythropoiesis and erythrophagocytosis in the spleen,25,56 anemia
in EVL is largely driven by CD41 T-cell–dependent alterations to the
BM niche supporting the final stages of erythropoiesis.25
In summary, our findings suggest that the mechanisms responsible
for thrombocytopenia are multifactorial, involving both defective BM
production and excessive clearance by peripheral tissues. However,
these changes appear rapidly and are completely reversible after
drug treatment and parasite clearance. These findings provide new


















































































































































Figure 5. Reversal of thrombocytopenia with the restoration of TPO production and organomegaly in infected mice after treatment. L donovani–infected mice
were treated with a single IV dose of AmBisome (8 mg/kg) at day 28 PI and bled weekly via tail vein for platelet counts. Platelet counts (A), MPV (B), and postmortem liver
weights (C) of AmBisome-treated and uninfected control mice. Data are representative of a single experiment and were analyzed with the unpaired Student t test comparing
means 6 SD of treated vs uninfected control at each time point. (D) Circulating TPO levels were measured weekly in serum samples of uninfected control (n 5 5) and treated
(n 5 3 at weeks 1, 2, 3, and 4) mice. Data are representative of a single experiment and analyzed using ANOVA with the post hoc Tukey’s test. (E) Hepatic Thpo mRNA
accumulation was measured using quantitative RT-PCR on postmortem liver samples of uninfected control (n 5 3) and treated (n 5 3) mice at each time point. Data are
representative of a single experiment and analyzed using the unpaired Student t test comparing the mean 6 SD of control vs treated mice. (F) Postmortem spleen weights (g)
of AmBisome-treated and uninfected control mice. Data are representative of a single experiment and analyzed using the unpaired Student t test comparing the mean 6 SD of
treated vs uninfected control at each time point. *P , .05; **P , .01; ***P , .001; ****P , .0001.





































































































complications in infections including VL and the management of
thrombocytopenia. In addition, we suggest that platelet counts
may be a useful surrogate for disease progression or treatment
response in both natural infection and experimental models.
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